In the Literature

Sacituzumab govitecan (Trodelvy), a Trop-2 antibody and topoisomerase inhibitor, showed promising results in a small clinical trial of patients with metastatic TNBC. These findings provided the basis for accelerated FDA approval of this agent in April 2020 for the treatment of patients with metastatic TNBC who have received ≥2 previous therapies in the metastatic setting, with full approval contingent on the results of the confirmatory phase 3 ASCENT study (Bardia A, et al. N Engl J Med. Read More ›

It is estimated that in 2020, there were 6.3 million cases and 3.3 million deaths globally of mouth, pharynx, larynx, esophageal, colon, rectum, liver, and breast cancer. These cancers have causal links to alcohol consumption. However, patterns of alcohol use continue to change over time across the world. With changes in alcohol consumption and more recent cancer incidence data, new estimates of the alcohol-attributable burden of cancer are needed. Read More ›

Regular aspirin use is considered the best chemoprevention strategy to reduce colorectal cancer (CRC) risk in middle-aged adults. This supported the US Preventive Services Task Force’s (USPSTF) recommendation of daily aspirin for CRC prophylaxis in adults aged 50 to 59 years and certain cardiovascular risk factors. The USPSTF, however, also recommends aspirin use in people aged ≥70 years, but the evidence for this is inconsistent. Read More ›

Esophageal cancer is a leading cause of cancer-related morbidity and mortality worldwide. Chemoradiotherapy followed by surgery is the standard of care for patients with resectable, locally advanced esophageal cancer. However, the risk for recurrence after this treatment remains high, especially among the majority of patients who do not have a pathologic complete response. Read More ›

Previous analyses have pointed to alarming shortages of oncology providers in the face of growing demand. No oncology workforce study, however, has assessed the link between geographic need for oncology services and the codependency between oncologists and nonphysician health professionals with an oncology subspecialty. A recent report on the state of cancer care in the United States examined the availability of physicians and oncology pharmacists and their geographic distributions throughout the country and compared it with the need for oncology services in each county. Read More ›

Rucaparib (Rubraca, Clovis Oncology) demonstrated promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration, according to results of a study published online in the Journal of Clinical Oncology. Read More ›

Black men with low-risk prostate cancer who were on active surveillance had an increased risk for disease progression and definitive treatment compared with their non-Hispanic White counterparts, but not increased mortality, according to the results of a recent study. Read More ›

Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read More ›

Patients with anemia and lower-risk myelodysplastic syndromes (MDS) in whom first-line erythropoiesis-stimulating agents (ESAs) are not effective generally become transfusion dependent. Luspatercept-aamt (Reblozyl), a recombinant fusion protein that binds transforming growth factor beta superfamily ligands to reduce SMAD2 and SMAD3 signaling, was approved by the FDA in November 2019 and has been studied in this patient population with promising results.

Read More ›

The discontinuation of oral oncology medications before the full-month supply has been finished results in medication waste, leading to increased costs for patients and for payers. Split fills allow for a 14- to 16-day supply for oral oncology medications rather than a full 28- to 30-day supply. Researchers compared the discontinuation rates, patient-reported adverse events, estimated pharmacy costs, and potential waste in patients with pharmacy benefit designs that included a split-fill option with patients who did not have this option (Staskon FC, et al. J Oncol Pract. 2019;15:e856-e862).

Read More ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: